Oxford, United Kingdom
GENinCode is a UK-based startup founded in 2018, specializing in clinical genetics and precision medicine. The company's slogan "Safeguarding your future health" underscores its focus on risk assessment and prediction of cardiovascular diseases such as thrombosis and familial hypercholesterolemia.
With cardiovascular disease being the leading cause of death and disability worldwide, accounting for 1 in every 4 deaths in the United States, GENinCode's advanced genomic technology and products play a crucial role in providing validated health information. The company aims to integrate traditional clinical measures with genetic information to offer comprehensive risk assessments and clinical recommendations, aiding healthcare practitioners in decision-making and empowering patients to manage their cardiovascular risk effectively.
GENinCode's technology and online reporting system SITAB® are designed to assist in assessing and predicting the onset of cardiovascular diseases, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Recently, the company secured a significant £4.00MPost-IPO Equity investment on 21 December 2023, indicating investor confidence in its innovative approach to leveraging genomics in healthcare.
The industries of biotechnology, healthcare, and life sciences stand to benefit from GENinCode’s advancements, potentially revolutionizing the landscape of preventive and personalized medicine.
